Skip to main content
. 2018 Jul 24;16(4):4353–4360. doi: 10.3892/ol.2018.9198

Figure 4.

Figure 4.

The cfDNA concentration in NSCLC patients with stable vs. progressive disease. (A) Comparison of serum cfDNA concentrations in NSCLC patients with progressive or stable disease. (B) Kaplan-Meier curves of PFS based on serum cfDNA levels in NSCLC patients. P-values were calculated by using the Mann-Whitney test. *P<0.05 and ***P<0.001 indicate statistical significance. cfDNA, cell-free DNA; NSCLC, non-small cell lung cancer; PFS, progression-free survival.